Verity Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Verity Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$640K	Buy	1,269 +17	+1%	+$8.98K	0.25%	112
2026 Q2	$672K	Buy	1,252 +88	+8%	+$45.1K	0.25%	108
2026 Q1	$609K	Buy	1,164 +6	+0.5%	+$2.87K	0.26%	110
2025 Q4	$674K	Sell	1,158 -102	-8%	-$52.1K	0.29%	95
2025 Q3	$578K	Sell	1,260 -457	-27%	-$170K	0.19%	120
2025 Q2	$520K	Buy	1,717 +157	+10%	+$46.8K	0.25%	100
2025 Q1	$517K	Buy	1,560 +70	+5%	+$23K	0.21%	110
2024 Q4	$460K	Buy	1,490 +24	+2%	+$6.75K	0.26%	90
2024 Q3	$311K	Buy	1,466 +101	+7%	+$25.8K	0.12%	154
2024 Q2	$382K	Sell	1,365 -209	-13%	-$49.8K	0.15%	125
2024 Q1	$420K	Sell	1,574 -1,115	-41%	-$263K	0.23%	113
2023 Q4	$622K	Buy	2,689 +2	+0.1%	+$350	0.4%	64
2023 Q3	$392K	Buy	2,687 +721	+37%	+$136K	0.29%	92
2023 Q2	$454K	Buy	1,966 +492	+33%	+$133K	0.34%	82
2023 Q1	$357K	Buy	1,474 +452	+44%	+$123K	0.21%	109
2022 Q4	$297K	Sell	1,022 -2,830	-73%	-$277K	0.25%	118
2022 Q3	$250K	Buy	+3,852	New	+$268K	0.26%	125
2022 Q1	$275K	Buy	2,801 +145	+5%	+$12.2K	0.17%	157
2021 Q4	$225K	Sell	2,656 -320	-11%	-$26.3K	0.13%	178
2021 Q3	$237K	Buy	2,976 +618	+26%	+$53.4K	0.15%	159
2021 Q2	$230K	Buy	2,358 +49	+2%	+$5.8K	0.13%	198
2021 Q1	$270K	Buy	2,309 +464	+25%	+$54.1K	0.16%	166
2020 Q4	$205K	Buy	+1,845	New	+$226K	0.14%	151
2015 Q4	–	Sell	-1,842	Closed	-$112K	–	90
2015 Q3	$112K	Sell	1,842 -492	-21%	-$35.5K	0.11%	88
2015 Q2	$182K	Buy	2,334 +719	+45%	+$60.3K	0.16%	85
2015 Q1	$110K	Sell	1,615 -739	-31%	-$63.4K	0.11%	78
2014 Q4	$218K	Sell	2,354 -63	-3%	-$6.51K	0.21%	68
2014 Q3	$254K	Sell	2,417 -412	-15%	-$57.3K	0.29%	52
2014 Q2	$405K	Sell	2,829 -114	-4%	-$16.7K	0.44%	44
2014 Q1	$456K	Buy	2,943 +218	+8%	+$42.9K	0.47%	35
2013 Q4	$500K	Buy	+2,725	New	+$499K	0.55%	23

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Verity Asset Management's MDGL Position: Q3 2026 in Review

Verity Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 1.4% in Q3 2026, buying an estimated $8.98K and bringing the position to 1,269 shares worth $640K. The position accounts for 0.25% of the portfolio, ranked #112.

Verity Asset Management first reported a position in MDGL in Q4 2013 and has held it in 31 quarters since. The position peaked at $674K in Q4 2025. 200 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Verity Asset Management held 1,269 shares of Madrigal Pharmaceuticals worth $640K as of Q3 2026.
Verity Asset Management bought 17 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $8.98K.
Madrigal Pharmaceuticals made up 0.25% of Verity Asset Management's portfolio in Q3 2026, its #112 holding.
Verity Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 31 quarters since.
Verity Asset Management's Madrigal Pharmaceuticals position peaked at $674K in Q4 2025.
200 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Verity Asset Management's 13F filing for Q3 2026, filed 30 Oct 2026.